Hyperacute serum (HAS) is a variation of platelet-rich plasma (PRP) that has been developed for clinical use and has been shown to outperform platelet-rich plasma (PRP) as a regenerative blood serum derivative. Ongoing research shows that hyperacute serum provides more robust support than PRP in mesenchymal stem cell (MSC) proliferation as well as lipogenic (enhances differentiation, indicating that it may be a better adjuvant in fat grafting and other regenerative procedures. In another study, the chondrocyte (cartilage cell) proliferation was significantly more induced by hyperacute serum (HAS) than by platelet-rich plasma (PRP).
Hyperacute serum (HAS) has been designed to avoid several disadvantageous effects of platelet release since it works through natural coagulation in a single-step preparation process, avoiding issues with the overconcentration of plasma derivatives, potentially negative effects of the anticoagulation necessary in the processing of the platelet-rich plasma (PRP) systems.
Interestingly, studies have observed that the most proliferative cell culture milieu was provided by HAS supplementation and not with PRP, despite the higher number of growth factors in the PRP. One explanation can be that the cells respond best to optimized conditions. Any deviation from this natural cellular environment, either too little or too much paracrine signals turn into inhibition or acts against each other on the same cell. Despite their seemingly similar preparation methods, serum derivatives can have very divergent biological effects, as it was demonstrated here between hyperacute serum (HAS) and PRP. Taken together, the five separate lines of experimental observations regarding the effect of hyperacute serum (HAS) point in the same direction:
The hyperacute serum seems to perform better in therapeutic protocols targeting the degenerative bone marrow niche (i.e., degenerative arthritic conditions).
Hyperacute serum (HAS) is safe, easily prepared, and effective. It seems to be generally more effective than platelet-rich plasma (PRP), especially as it relates to degenerative/arthritic conditions.
“Our observations have convinced me that hyperacute serum is a very strong alternative to any serum or plasma derivatives that are used in stem cell activation. This serum is far more reliable in supporting the cells than the notoriously variable PRP,” said Ms. Olga Kuten, first author of the Tissue Engineering study.
"Dr. Chelnis is AWEmazing! He is an extremely knowledgeable and highly-skilled professional. He is very personable, courteous and takes his time to address all concerns and answer every single question. He has First-Class bedside manners and the results of his work are OUTSTANDING! His entire staff is just as amazing, friendly and accommodating and they go the “extra mile” to ensure your experience is the best one ever — mine was… it was an absolute pleasure! I HIGHLY recommend Dr. Chelnis!”